Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 31

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 31
---
 at an exercise price of $2.95 per share, subject to certain adjustments. The February 2025 Warrants
are exercisable upon issuance and expire twenty-four months from the date of issuance.

The Company filed a registration statement (the
“Selling Shareholder S-1”) with the SEC that registered the February 2025 Shares and the shares underlying the February 2025
Warrants, which was declared effective by the SEC on April 2, 2025.

The issuance of the February 2025 Warrants pursuant
to the February 2025 Securities Purchase Agreement and issuance of the February 2025 Placement Agent Warrants (as defined below) were
made pursuant to the exemption from the registration requirements under the Securities Act, available to the Company under Section 4(a)(2)
promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act due to the fact the offering of the February
2025 Warrants and the February 2025 Placement Agent Warrants thereunder did not involve a public offering of securities.

The Company paid Wainwright & Co., LLC (“Wainwright”),
the placement agent in the February 2025 Offering, a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering
and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid for certain non-accountable
expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to the placement agent warrants
to purchase up to 22,554 shares of Common Stock (the “February 2025 Placement Agent Warrants”). The February 2025 Placement
Agent Warrants have an exercise price equal to $4.469 per share and are exercisable upon issuance, or February 6, 2025, and expire twenty-four
months from the date of issuance.

The Company received net proceeds of $908,627
from the offering, after deducting estimated offering expenses paid by the Company, including the placement agent fees. The Company has
used and intends to use the net proceeds from the offering for general corporate purposes, including working capital.

January 2025 Offering

On January 28, 2025, we entered into a securities
purchase agreement (the “January 2025 Securities Purchase Agreement”) with certain institutional investors (the “January
2025 Purchasers”) pursuant to